A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer

PharmacoEconomics ◽

10.2165/00019053-200422090-00003 ◽

2004 ◽

Vol 22 (9) ◽

pp. 581-589 ◽

Author(s):

Jeremy Holmes ◽

David Dunlop ◽

Lindsay Hemmett ◽

Peter Sharplin ◽

Uday Bose

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

10.1186/1471-2407-10-26 ◽

2010 ◽

Vol 10 (1) ◽

Author(s):

Yumi Asukai ◽

Amparo Valladares ◽

Carlos Camps ◽

Eifiona Wood ◽

Kaisa Taipale ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

PCN90 Cost-Effectiveness Analysis of Erlotinib Versus Docetaxel, Pemetrexed for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Russia

Value in Health ◽

10.1016/j.jval.2011.08.1191 ◽

2011 ◽

Vol 14 (7) ◽

pp. A450 ◽

Author(s):

T.T.T. Nguyen ◽

R. Yagudina ◽

A. Kulikov

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

The Cost Effectiveness Analysis of PD-1 And PD-L1 Agents Compared with Docetaxel for Second-Line Treatment of Advanced Non-Small Cell Lung Cancer

Value in Health ◽

10.1016/j.jval.2018.04.191 ◽

2018 ◽

Vol 21 ◽

pp. S30

Author(s):

YH Bae-Shaaw ◽

JW Hay

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

Download Full-text

Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China

Advances in Therapy ◽

10.1007/s12325-021-01889-2 ◽

2021 ◽

Vol 38 (10) ◽

pp. 5116-5126 ◽

Author(s):

Jinhong Gong ◽

Qian Wan ◽

Jingjing Shang ◽

Xiaodan Qian ◽

Dan Su ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e31822f657a ◽

2011 ◽

Vol 6 (12) ◽

pp. 2097-2103 ◽

Author(s):

Ian Cromwell ◽

Kimberly van der Hoek ◽

Barbara Melosky ◽

Stuart Peacock

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Words (Excluding Tãtle and Authors: 300) Title: Cost-Effectiveness Analysis of Nivolumab for the Treatment of Second-Line Advanced Squamous Non-Small Cell Lung Cancer (Nsclc) in Spain

Value in Health ◽

10.1016/j.jval.2016.09.2210 ◽

2016 ◽

Vol 19 (7) ◽

pp. A732-A733 ◽

Author(s):

P González García ◽

E Felip ◽

P Garrido ◽

J Trigo ◽

N Ortega-Joaquin ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting

10.1136/ejhpharm-2018-eahpconf.5 ◽

2018 ◽

Author(s):

AB Fernández Román ◽

C Bravo Lázaro ◽

J Letellez Fernández ◽

N Herrero Muñoz ◽

A Andrés Rosado ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Healthcare Setting ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

PharmacoEconomics ◽

10.1007/s40273-021-01022-9 ◽

2021 ◽

Author(s):

Yong-Jin Kim ◽

Mark Oremus ◽

Helen H. Chen ◽

Thomas McFarlane ◽

Danielle Fearon ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Cancer Management and Research ◽

10.2147/cmar.s223441 ◽

2019 ◽

Vol Volume 11 ◽

pp. 9195-9202 ◽

Author(s):

Maobai Liu ◽

Longfeng Zhang ◽

Qishu Huang ◽

Na Li ◽

Bin Zheng ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness Analysis of Robotic-assisted Lobectomy for Non-small Cell Lung Cancer

The Annals of Thoracic Surgery ◽

10.1016/j.athoracsur.2021.06.090 ◽

2021 ◽

Author(s):

Brendan T. Heiden ◽

Joshua D. Mitchell ◽

Eric Rome ◽

Varun Puri ◽

Bryan F. Meyers ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Robotic Assisted ◽

Effectiveness Analysis

Download Full-text